N/A N=152 Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
Anorexia Nervosa
Primary: Rate of Weight Change — 0.095; 0.260 kg/m^2 per month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=110 Effects of Anorexia Nervosa on Bone Mass in Adolescents
Anorexia Nervosa
Primary: Percent Change in Spine Bone Density Over the Study Duration (18 Months) — 2.6; 0.3 Percent change — p=<0.05
Phase 4 N=41 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Anorexia Nervosa
Primary: Change in Eating Disorder Inventory-2 Drive for Thinness Subscale (DT) — 1.36; 3.93 units on a scale
N/A N=177 Shifting Perspectives: Enhancing Outcomes in Anorexia Nervosa With CRT
Anorexia Nervosa
Primary: Change in Cognitive Flexibility - Condition 4 Trail Making Test of DKEFS — 11.89; 10.94; 11.47; 11.14 score on a scale — p=.507
Early Phase 1 N=13 Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia Nervosa
Primary: Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI)…
N/A N=100 Self-Control in Bulimia Nervosa
Bulimia Nervosa
Primary: Brain Activation Associated With P(Stop) — 0.02; 0.11; 0.04; 0.05 BOLD Signal
Phase 3 N=77 Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001
N/A N=71 An fMRI Study of Self-regulation in Adolescents With Bulimia Nervosa
Eating Disorders
Primary: Magnetic Resonance Imaging Scans — 2.98; 2.96 mm — p=.03
N/A N=59 Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
Eating Disorders
Primary: Body Mass Index (BMI) Z-score — -0.72; -0.02 z-score
Phase 3 N=75 Effects of Anorexia Nervosa on Peak Bone Mass
Anorexia Nervosa
Primary: Change in Bone Density Over a 12-month Period — 0.045; 0.280 score on a scale — p=.109
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 2 N=90 Hormonal Factors in the Treatment of Anorexia Nervosa
Anorexia Nervosa · Eating Disorder · Anxiety
Primary: Change From Baseline in Weight — 0.1; 1.5 kilograms
Phase 4 N=93 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
Anorexia Nervosa · Eating Disorders
Primary: Proportion of Patients Remaining in Study at 1 Year — 0.265; 0.315 proportion of participants — p=0.57
Phase 4 N=88 Monoamine Contributions to Neurocircuitry in Eating Disorders
Eating Disorder
Primary: 5-HT Transporter Binding as Measured During the PET Scan — 1.68; 1.54; 1.46; 1.60 binding potential (BPND) — p=> 0.05
Phase 2 N=34 Olanzapine in the Treatment of Patients With Anorexia Nervosa
Anorexia Nervosa
Primary: Body Mass Index (BMI) (kg/m^2) — 19.66; 20.30; 19.66; 20.30 kg/m^2
Phase 4 N=22 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
Eating Disorders
Primary: Change From Baseline in Weight (Lbs.) at 12 Weeks — 2.2; -1.2 lbs
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
N/A N=90 Helping HAND: Healing Anorexia Nervosa Digitally
Anorexia Nervosa
Primary: Effectiveness of the Mobile App Conditions, Compared to Referral to Usual Care, in Changing Eating Disorder Psychopathology, as Assessed by the Eating Disorder…
N/A N=159 Development of Eating Disorders Symptoms Among Children
Eating Disorders Symptoms
Primary: Number of Participants With >20 on the 26 Children Eating Attitudes Test — 26; 4 Participants
N/A N=101 Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa
Anorexia Nervosa
Primary: Change From Baseline in C-telopeptides — 0.083; -0.027 ng/mL/day
Phase 2 N=23 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
Eating Disorders
Primary: Weight Gain — 6.2; 1.5 lbs
N/A N=32 App-Based Mindfulness Training for Individuals With Anorexia Nervosa and Bulimia Nervosa
Anorexia Nervosa · Bulimia Nervosa · Anorexia Nervosa, Atypical
Primary: Feasibility of Module Completion — 87.8 percentage of modules completed
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
N/A N=23 PET Imaging Study of Recovered Anorexics
Anorexia Nervosa
Primary: Serotonin Receptor 1A Binding Potential In Regions of Interest (ROI) Accounting for Binding Potential in a Region Without Serotonin 1A Receptors — 5.97; 5.89; 6.66; 6.91…
N/A N=50 Cognitive Behavioral Therapy for Adolescent Binge Eating and Loss of Control Eating
Binge Eating · Eating Disorders in Adolescence · Overweight and Obesity
Primary: Binge (Loss-of-control) Eating Episode Frequency — 1.52; 6.05 episodes of behavior — p=.01
Phase 2 N=10 Neurobiology of Bulimia Nervosa
Bulimia Nervosa
Primary: Change in Binge Eating Sum Score — -0.60; 0.89 score on a scale
Phase 2 N=24 Treatment of Anxiety and Anorexia Nervosa in Adolescents
Anxiety · Anorexia Nervosa
Primary: Medication Side Effects Score — 9.5; 6.2; 6.4; 4.1 Score on a scale
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
N/A N=41 Parent Emotion Coaching for Anorexia Nervosa
Anorexia Nervosa · Atypical Anorexia Nervosa
Primary: Criticism — 5.5; 3.7; 3.7; 4.3 score on a scale
Phase 2 N=21 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Bone Metabolism — 34.3; 10.4 ng/ml